CooperVision: Expanding Myopia Management Access

As myopia rates surged globally, CooperVision—who developed the first FDA-approved contact lens proven to slow its progression—faced increasing competition and evolving clinical expectations. To maintain leadership, the company expanded its MiSight 1 day portfolio by introducing a silicone hydrogel version and launching the original product in Japan, a key global market.

Working with long-time partner McDougall Communications, CooperVision positioned these moves as defining milestones in the myopia management category. Grounded in science and clinical credibility, the campaign leveraged global media outreach, executive thought leadership, and regionally tailored messaging to reinforce the brand’s role as a pioneer and innovator.

The program exceeded all major objectives, generating extensive media attention and reaching eye care professionals worldwide. It also achieved category-leading share of voice, secured influential coverage in Japan, and sustained global momentum well beyond launch, strengthening CooperVision’s position at the forefront of myopia control innovation.